reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
MUSA MURPHY USA INC.
MOS MOSAIC COMPANY
HNRG HALLADOR ENERGY CO.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GT GOODYEAR TIRE & RUBBER COMPANY
FAST FASTENAL COMPANY
BGS B&G FOODS INC.
CNR. CANADIAN NATIONAL RAILWAY COMPANY
AGX ARGAN INC.
LEU CENTRUS ENERGY CORPORATION
GRPN GROUPON INC.
IPI INTREPID POTASH
SBTX SILVERBACK THERAPEUTICS
SDGR SCHRODINGER
RGC REGENCELL BIOSCIENCE HLDGS LTD
PPTA PERPETUA RESOURCES CORP
MPTI M TRON INDUSTRIES INC
ASPI ASP ISOTOPES INC
ANG ANGLOGOLD ASHANTI LIMITED
AZ A2Z CUST2MATE SOLUTIONS CORP
USAU US GOLD CORP
SLNO SOLENO THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c...
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made ...
Schrödinger Expands Board of Directors with Appointment of Bridget van...
NEW YORK--(BUSINESS WIRE)-- , Inc. (Nasdaq: SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: Bridget van Kralingen was appointed to Schrödinger’s Board of Directors in March 2025. (Photo: Business Wire) “Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “Bridget’s leadership experience overseeing strategic initiatives at global ...
Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial...
NEW YORK--(BUSINESS WIRE)-- (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its financial outlook for 2025. “We are delighted with Schrödinger’s excellent financial performance in 2024. Software revenue growth exceeded our expectations, showing the resilience of our business through changing industry cycles and the impact of large contract renewals. Our drug discovery collaboration portfolio is expanding, driven by our new agreement with Novartis and expanded collaborations with Otsuka and Lilly, and we expect to re...
Schrödinger to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T. Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 18, 2025 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the even...
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c...
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 17, 2025, the company granted restricted stock units (RSUs) with respect to 5,445 shares of the company’s common stock to five newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rul...
Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Re...
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR) will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug developm...
- Dave Nicoski
- Ross LaDuke
TWI TITAN INTERNATIONAL INC.
TRIP TRIPADVISOR INC.
TITN TITAN MACHINERY
SLP SIMULATIONS PLUS
RYI RYERSON HOLDING CORPORATION
QCOM QUALCOMM INC
PCRX PACIRA BIOSCIENCES INC.
MOS MOSAIC COMPANY
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
IVZ INVESCO LTD.
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
DLTR DOLLAR TREE INC.
DDD 3D SYSTEMS CORPORATION
CERS CERUS CORP.
AVD AMERICAN VANGUARD
ANIP ANI PHARMACEUTICALS INC.
AGCO AGCO CORPORATION
UPS UNITED PARCEL SERVICE INC. CLASS B
OSTK OVERSTOCK.COM INC.
GDEN GOLDEN ENTERTAINMENT
FRX_CN FENNEC PHARMACEUTICALS
ODEL.N0000 ODEL PLC
BRKS BROOKS AUTOMATION INC.
CCV COUNTERPATH
TDC TERADATA CORPORATION
BHF BRIGHTHOUSE FINANCIAL INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
SIBN SI-BONE
PINS PINTEREST INC. CLASS A
VIAC VIACOMCBS INC. CLASS B
ORIC ORIC PHARMACEUTICALS
THRY THRYV HOLDINGS
CERT CERTARA
ONTF ON24
SMTI SANARA MEDTECH
SDGR SCHRODINGER
COUR COURSERA INC
BBWI BATH & BODY WORKS INC
DH DEFINITIVE HEALTHCARE CORP
VERV VERVE THERAPEUTICS INC
PTLO PORTILLOS INC
DCGO DOCGO INC
EHAB ENHABIT INC
SVV SAVERS VALUE VILLAGE INC
QIPT PATIENT HOME MONITORING CORP
HUM HAMILTON U.S. MID-CAP FINANCIALS ETF
CXM SPRINKLR INC
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Confere...
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference. The live presentation will take place on Wednesday, December 4, 2024 at 8:30 a.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for dr...
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
NEW YORK--(BUSINESS WIRE)-- (Nasdaq: SDGR), today announced that it is broadening and accelerating its initiative to expand the company’s computational platform to predict toxicology risk early in drug discovery. The goal of the initiative, , is to develop a computational solution designed to improve the properties of novel drug development candidates and reduce the risk of development failure associated with binding to off-target proteins, which can be associated with serious side effects. In conjunction with this expansion, Schrödinger received an additional $9.5 million from the Bill & M...
Schrödinger Reports Third Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)-- (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier today, Schrödinger announced a multi-target research and licensing collaboration with Novartis. Under the terms of the agreement, Novartis will pay Schrödinger $150 million upfront, and Schrödinger will also be eligible to receive up to $2.3 billion in milestone payments. Schrödinger also announced an expanded three-year software agreement that substantially increases Novartis's access to Schrödinger’s computation...
Schrödinger Announces Multi-Target Collaboration and Expanded Software...
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s portfolio for further development. The companies also announced an expanded three-year software agreement that substantially increases Novartis's access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform. This expanded access enables Novartis to deploy Schrödinger’s full suite of drug discovery technologies at industry-leading scale across its research s...
Schrödinger to Present at Jefferies London Healthcare Conference
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 20, at 8:30 a.m. GMT (3:30 a.m. ET). The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutic...
Schrödinger to Announce Third Quarter 2024 Financial Results on Novemb...
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2024 financial results on Tuesday, November 12, 2024, before the financial markets open. The company will host a conference call and webcast at 8:00 a.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are disco...
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c...
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on September 13, 2024, the company granted restricted stock units (RSUs) with respect to 7,025 shares of the company’s common stock to eight newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a mater...
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c...
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on August 14, 2024, the company granted restricted stock units (RSUs) with respect to 7,500 shares of the company’s common stock to 13 newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material in...
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The live presentation will take place on Wednesday, September 4, 2024, at 3:20 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way t...
Schrödinger Reports Strong Second Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)-- (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the second quarter of 2024. “We are very pleased with our results for the second quarter. We delivered 21% software revenue growth, and we see many opportunities for customers to increase their scale of adoption of our technology. Our recently announced predictive toxicology initiative reflects our commitment to investing in the science underlying our platform to drive future growth,” said Ramy Farid, ...
Schrödinger Launches Initiative to Significantly Expand Application of...
NEW YORK--(BUSINESS WIRE)-- (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that it is embarking on an initiative to expand its computational platform to predict toxicology risk early in drug discovery. The goal of the initiative is to develop a computational solution designed to improve the properties of novel drug development candidates and reduce the risk of development failure associated with binding to off-target proteins, which can be associated with serious side effects. This initiative is an ...
Schrödinger to Announce Second Quarter 2024 Financial Results on July ...
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are dis...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.